Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PK and Safety of Linzagolix in Renal Impairment
NCT03961932Phase 1Completed
- Sponsor
- ObsEva SA
- Start
- May 2019
- Primary completion
- Jan 2020
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label trial of linzagolix in Uterine Fibroids (UF) (5 arms), sponsored by ObsEva SA. Primary endpoints: Maximum Plasma Concentration, Time to Maximum Plasma Concentration and 2 more. Started May 2019; status: completed.
02
Drugs
linzagolix
03
Conditions
Uterine Fibroids (UF)
Beyond the preview
Go deeper on NCT03961932.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03961932.